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Human T-cell leukemia virus type 1 (HTLV-1) is a replication-competent human retrovirus associated with two distinct types
of disease only in a minority of infected individuals: the malignancy known as adult T-cell leukemia (ATL) and a chronic
inﬂammatory central nervous system disease HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP). Although
the factors that cause these diﬀerent manifestations of HTLV-1 infection are not fully understood, accumulating evidence suggests
thatcomplexvirus-hostinteractionsplayanimportantroleindeterminingtheriskofHAM/TSP.Thisreviewfocusesontheroleof
the immune response in controlling or limiting viral persistence in HAM/TSP patients and the reason why some HTLV-1-infected
people develop HAM/TSP whereas the majority remains asymptomatic carriers of the virus.
1.Introduction
Human T-cell leukemia virus type 1 (HTLV-1) infection is
of particular interest to the ﬁeld of immunology as well
as microbiology because HTLV-1 is never eliminated from
the host in spite of vigorous cellular and humoral immune
responses against the virus but causes no disease in vast
majority of infected subjects (asymptomatic carriers:ACs).
Although only approximately 2%-3% develop adult T cell
leukemia (ATL) [1, 2] and another 0.25%–3.8% develop
chronic inﬂammatory diseases involving the central ner-
vous system (HTLV-1-associated myelopathy/tropical spastic
paraparesis: HAM/TSP) [3, 4], evaluation of the individual
risk for developing diseases in each ACs would certainly be
of considerable importance especially in HTLV-1 endemic
area such as southern Japan, the Caribbean, Central and
South America, the Middle East, Melanesia, and equatorial
regions of Africa [5]. However, many fundamental questions
are remained to be solved. First, how does HTLV-1 persist in
the individual host in spite of strong host immune response?
Second, why do some HTLV-1-infected people develop
consequent diseases such as ATL or HAM/TSP, whereas the
majority remains asymptomatic carriers of the virus? Third,
how is the inﬂammatory lesion in HAM/TSP initiated and
maintained, and why is the inﬂammation speciﬁcally in
thoracic spinal cord? This review summarizes the past and
recent works for HAM/TSP attempting to resolve each of
these questions.
2.ClinicalandPathological
Features of HAM/TSP
HTLV-1 is classiﬁed as a complex retrovirus in the genus
DeltaretrovirusofthesubfamilyOrthoretrovirinaeandinfects
10–20 million people worldwide [6–8]. HTLV-1 can be
transmitted through sexual contact [9], injection drug use
[8], and breastfeeding from mother to child [10, 11].
Although HTLV-1 infection is associated with a range of
nonmalignant chronic inﬂammatory diseases in the eyes, the
lungs,ortheskeletalmuscles[7],HAM/TSPisthebestrecog-
nized with chronic progressive myelopathy characterized by
spastic paraparesis, sphincter dysfunction, and mild sensory
disturbance in the lower extremities [12]. To date, more2 Interdisciplinary Perspectives on Infectious Diseases
than 3,000 cases of HAM/TSP patients have been reported
in HTLV-1 endemic areas. Sporadic cases have also been
described in nonendemic areas such as the United States
andEurope,mainlyinimmigrantsfromanHTLV-1endemic
area. Among ACs, the lifetime risk of developing HAM/TSP,
which is diﬀerent among diﬀerent ethnic groups, ranges
between 0.25% and 4%. It has been reported that the annual
incidence of HAM/TSP is higher among Jamaican subjects
than among Japanese subjects (20 versus 3 cases/100,000
population), with a two to three times higher risk for women
in both populations [13–16].
Pathological analysis of HAM/TSP autopsy materials
indicates that the disease aﬀects the spinal cord, predomi-
nantly at the thoracic level [17–19]. Loss of myelin and axons
in the lateral, anterior, and posterior columns is associated
with perivascular and parenchymal lymphocytic inﬁltration
with the presence of foamy macrophages, proliferation of
astrocytes, and ﬁbrillary gliosis. The presence of atypical
lymphocytes (so-called “ﬂower cells”) in peripheral blood
and cerebrospinal ﬂuid (CSF), a moderate pleocytosis,
and raised protein content in CSF are typically found in
HAM/TSP patients. Oligoclonal bands, raised concentra-
tions of inﬂammatory markers such as neopterin, tumor
necrosis factor (TNF)-α, interleukin (IL)-6 and interferon
(IFN)-γ, and an increased intrathecal antibody synthesis
speciﬁc for HTLV-1 antigens have also been described
[20]. Clinical progression of HAM/TSP is associated with
increasedproviralloadinindividualpatients,andtheratioof
proviral loads in CSF cells/in peripheral blood mononuclear
cells (PBMCs) is signiﬁcantly associated with clinically pro-
gressive disease [21]. The major histocompatibility complex
(MHC) class I tetramer analysis of lymphocytes isolated
from the CSF of HAM/TSP patients showed even higher fre-
quenciesofHTLV-1Tax11-19-speciﬁc,HLA-A∗02-restricted
CD8+ lymphocytes compared to those of PBMCs [22].
Therefore, an increased proliferation or migration of HTLV-
1-infected and/or HTLV-1-speciﬁc lymphocytes to the cen-
tral nervous system (CNS) might be closely associated with
HAM/TSP pathogenesis [23].
3. Risk Factors for HAM/TSP
3.1. Host Genetics. Previous population association study of
202 cases of HAM/TSP and 243 ACs in Kagoshima, HTLV-
1 endemic southern Japan, revealed that one of the major
risk factors is the HTLV-1 proviral load. The median proviral
load was more than ten times higher in HAM/TSP patients
than in ACs, and a high proviral load was also associated
with an increased risk of progression to disease [24]. Higher
proviralloadinHAM/TSPpatientsthaninACswasobserved
in other endemic area, such as the Caribbean [25], South
America [26], and the Middle East [27]. It was suggested
that genetic factors such as human leukocyte antigen (HLA)
are related to the high proviral load in HAM/TSP patients
and genetic relatives. In southern Japan, possession of the
HLA-class I genes HLA-A∗02 and Cw∗08 was associated
with a statistically signiﬁcant reduction in both HTLV-1
proviral load and the risk of HAM/TSP, whereas possession
of HLA-class I HLA-B∗5401 and class II HLA-DRB1∗0101
predisposes to HAM/TSP in the same population [28, 29].
Since the function of class I HLA proteins is to present
antigenic peptides to cytotoxic T lymphocytes (CTL), these
results imply that individuals with HLA-A∗02 or HLA-
Cw∗08 mount a particularly eﬃcient CTL response against
HTLV-1, which may be an important determinant of HTLV-
1 proviral load and the risk of HAM/TSP. Further analysis to
look at nonHLA host genetic factors revealed that nonHLA
gene polymorphism also aﬀects the risk for developing
HAM/TSP. For example, the TNF-α promoter −863 A
allele [30], and the longer CA repeat alleles of matrix
metalloproteinase (MMP)-9 promoter [31] predisposed to
HAM/TSP,whereasIL-10-592A[32],Stromalderivedfactor
(SDF)-1 +801A [30] and IL-15 +191 C alleles [30]c o n f e r r e d
protection against HAM/TSP. The polymorphisms of MMP-
9 and IL-10 promoter each linked to the HTLV-1-encoded
transactivator Tax-mediated transcriptional activity of each
gene [31, 32].
3.2. HTLV-1 Genotype. Although most studies of HTLV-1
genotype have reported no association between variants of
HTLV-1 and the risk of HAM/TSP, Furukawa et al. reported
the association between HTLV-1 tax gene variation and the
risk of HAM/TSP [33]. The tax subgroup A that belongs
to cosmopolitan subtype A was more frequently observed
in HAM/TSP patients and this eﬀect was independent of
protective allele HLA-A∗02. HLA-A∗02 appeared to give
protection against only one of the two prevalent sequence
variants of HTLV-1, tax subgroup B that belongs to cos-
mopolitan subtype B but not against tax subgroup A in
Japanese population [33]. Interestingly, HLA-A∗02 appears
not to give protection against infection with cosmopolitan
subtype A in a population in Iran [27]. These ﬁndings
suggest that both host genetic factors and HTLV-1 subgroup
play a part in determining the risk of HAM/TSP.
4. The ImmuneResponse to HTLV-1
4.1. The Humoral Immune Response. In HTLV-1 infection,
anti-HTLV-1 antibody that often includes IgM is detected
in all infected individuals, either ACs or patients with
HAM/TSP[34].IthasbeenreportedthatHAM/TSPpatients
generally had higher anti-HTLV-1 antibody titer than ACs
with the similar HTLV-1 proviral load [34–36]. These data
suggest that there was persistent expression of HTLV-1
proteins in vivo and the existence of an augmented humoral
immuneresponsetoHTLV-1inHAM/TSPpatients.Interest-
ingly, although antibody responses to the immunodominant
epitopes of the HTLV-1 Envelope (Env) proteins were similar
in all of three clinical groups (HAM/TSP, ATL, and ACs),
reactivitytofourTaximmunodominantepitopeswashighest
in HAM/TSP (71%–93%) than ATL patients (4%–31%) or
ACs (27%–37%) [37]. In 2002, Levin et al. reported that
antibodies that recognize HTLV-1 Tax protein can cross-
react with a heterogenous nuclear riboprotein (hnRNP)-A1,
suggestingintriguingevidenceforantigenmimicryinHTLV-
1 infection [38]. However, since the host protein hnRNP-A1
is not conﬁned to the central nervous system but is widely
expressed [39] and is not normally accessible to antibodyInterdisciplinary Perspectives on Infectious Diseases 3
attack, it is unlikely that anti-Tax antibody explains the
onset or initial tissue damage of HAM/TSP. Rather, anti-Tax
antibody might be associated with subsequent inﬂammation
following initial tissue damage and disruption of blood brain
barrier, which is probably caused by the antiviral immune
responsestoHTLV-1andinducesthereleaseofautoantigens.
4.2. The Natural Killer (NK) Cell Response. Previous reports
indicated that patients with HAM/TSP had both a lower
frequency and a lower activity of NK cells (especially the
CD3+CD16+ subset) than ACs, although the results were
not normalized with respect to the proviral load [40]. Since
an important mechanism of induction of NK cell-mediated
killing is recognition by the NK cell of a complex of the
nonpolymorphic MHC molecule HLA-E bound to a peptide
derived from the signal sequence of some other MHC
class I molecules, the synthetic tetramers of HLA-E with
the HLA-G signal sequence peptide were used to identify
NK cells in HAM/TSP patients [41]. The results clearly
showed a lower frequency of HLA-E tetramer-binding cells
in HAM/TSP patients than ACs, and as in the earlier studies
[40], this reduction in frequency was particularly notable in
the CD3+ cells whereas there was no signiﬁcant diﬀerence
in the frequency of HLA-E tetramer-binding CD3− cells
between patients with HAM/TSP and ACs [41]. Recent data
also suggest that the frequency of invariant NKT cells in
the peripheral blood of HAM/TSP patients is signiﬁcantly
decreased when compared with healthy subjects and/or ACs
[42, 43]. These ﬁndings indicated that the activity of the NK
or NKT cell response was associated with the presence or
absence of HAM/TSP. Interestingly, previous uncontrolled
preliminary trial of viable Lactobacillus casei strain Shirota
containingfermentedmilkforHAM/TSPpatientsresultedin
signiﬁcant increase of NK cell activity with improvements in
clinical symptoms [44]. Thus, circulating NK and NKT cells
might also play an important role in the disease progression
and the pathogenesis of HAM/TSP.
4.3. The Regulatory T Cells (Tregs). It has been reported that
HTLV-1 preferentially and persistently infects CD4+CD25+
lymphocytes in vivo [45], which contains the majority of
the Foxp3+ Tregs [46]. In HAM/TSP patients, the percentage
of Foxp3+ Tregs in CD4+CD25+ cells is lower than that in
ACs and uninfected healthy controls [45, 47] whereas the
percentage of Foxp3+ cells in the CD4+ population tended
to be higher in the HAM/TSP patients than in the ACs [48–
50]. As CD25 is induced by HTLV-1 Tax oncoprotein [51],
it is most likely that the proportion of Foxp3+ cells falls
in the CD4+CD25+ population, which contain both Tregs
and activated nonTregs, in HTLV-1-infected individuals
especially HAM/TSP patients. Interestingly, the frequency
of HTLV-1 negative Foxp3+CD4+ cells positively correlated
with the HTLV-1 proviral load [23, 49] and the CTL activity
negatively correlated with the frequency of HTLV-1 negative
Foxp3+CD4+ cells [49]. These data suggest that an increase
in HTLV-1 negative FoxP3+CD4+ Tregs is one of the chief
determinants of the eﬃciency of T cell mediated immune
control of HTLV-1. If such Tregs reduce CTL activity, which
in turn increases the HTLV-1 proviral load, this activity
increases the risk for developing HAM/TSP.
4.4. The CD4+ Helper T Cell Response. It is well known that
antiviral CD4+ T cell responses are of central importance
in driving B-cell and CD8+ T-cell responses in vivo. The
HTLV-1 antigen most commonly recognized by CD4+ T
cells is the Env protein [52, 53], in contrast with the
immunodominance of Tax in the CD8+ Tc e l lr e s p o n s e[ 54–
56]. At a similar proviral load, patients with HAM/TSP had
signiﬁcantly increased frequency of virus-speciﬁc CD4+ T-
cells compared to that of ACs [53, 57]. The antiviral T
helper (Th)1 phenotype is also dominant among HTLV-
1-speciﬁc CD4+ T cells in both ACs and patients with
HAM/TSP [58], and there is a higher frequency of IFN-γ,
TNF-α, and IL-2 production by CD4+ T cells in patients
with HAM/TSP compared to ACs of a similar proviral
load [58, 59]. A role for CD4+ T cells in initiating and
causingHAM/TSPisalsoconsistentwiththeimmunogenetic
observations that the possession of HLA-DRB1∗0101, which
restricts immunodominant epitope of HTLV-1 Env gp21,
was associated with susceptibility to HAM/TSP in inde-
pendent HTLV-1-infected populations in southern Japan
[28, 29] and northeastern Iran [27]. Accordingly, a synthetic
tetramer of DRB1∗0101 and the immunodominant HTLV-1
Env380–394 peptide was used to analyze Env-speciﬁc CD4+
T cells directly ex vivo [57]. The results showed that the
frequency of tetramer+CD4+ T cells was signiﬁcantly higher
in HAM/TSP patients than in ACs with similar proviral load.
Moreover, direct ex vivo analysis of tetramer+CD4+ Tc e l l s
from two unrelated DRB1∗0101 positive HAM/TSP patients
indicatedthatcertainTcellreceptor(TCR)Vβsw er eutiliz ed
and antigen-speciﬁc amino acid motifs were identiﬁed in
complementarity determining region (CDR) 3 from both
patients. These data suggest that the observed increase in
virus-speciﬁc CD4+ T cells in HAM/TSP patients, which
may contribute to CD4+ T cell-mediated antiviral immune
responses and to an increased risk of HAM/TSP, was not
simply due to the rapidly growing HTLV-1-infected CD4+
T cells but was the result of in vivo selection by speciﬁc
MHC-peptide complexes, as observed in freshly isolated
HLA-A∗0201/Tax11-19 tetramer+ CD8+ T cells [60]a n d
muscle inﬁltrating cells from HAM/TSP patients and HTLV-
1-infected polymyositis patients [61].
4.5. The Cytotoxic T Lymphocyte (CTL) Response. Previous
reports indicated that the HTLV-1-speciﬁc CD8+ CTL is
typically abundant, chronically activated, and mainly tar-
geted to the viral transactivator protein Tax [62]. Also, as
already mentioned, the median proviral load in PBMCs of
HAM/TSP patients was more than ten times higher than that
in ACs, and a high proviral load was also associated with an
increased risk of progression to disease [24]. Furthermore,
HLA-A∗02 and HLA-Cw∗08 genes were independently and
signiﬁcantlyassociatedwithalowerproviralloadandalower
risk of HAM/TSP [28, 29], and CD8+ T cells eﬃciently kill
autologous Tax-expressing lymphocytes in fresh PBMCs in
HTLV-1-infectedindividuals [63].These datahave raised the
hypothesis that the class I-restricted CD8+ CTL response4 Interdisciplinary Perspectives on Infectious Diseases
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Figure 1: Hypothesis for the pathogenesis of Human T-cell leukemia virus type 1- (HTLV-1-)associated myelopathy/tropical spastic paraparesis
(HAM/TSP). In patients with HAM/TSP, genetically determined less eﬃcient CTL response against HTLV-1 may cause higher proviral
load and antigen expression, leading in turn to activation and expansion of antigen-speciﬁc T cell responses, subsequent induction
of large amounts of proinﬂammatory cytokines and chemokines, and progression of HAM/TSP development. It is also possible that
the immunoglobulin G speciﬁc to HTLV-1-Tax, which cross-reacts with heterogeneous nuclear ribonuclear protein-A1 (hnRNP-A1), is
associated with subsequent inﬂammation following initial tissue damage.
plays a critical part in limiting HTLV-1 replication in vivo
and that genetically determined diﬀerences in the eﬃciency
of the CTL response to HTLV-1 account for the risk for
developing HAM/TSP. However, since the frequency of
HTLV-1-speciﬁc CD8+ T cells was signiﬁcantly elevated in
HAM/TSP patients than in ACs [64, 65] and these cells have
the potential to produce proinﬂammatory cytokines [66],
thereisadebateontheroleofHTLV-1-speciﬁc-CD8+ Tcells,
that is, whether these cells contribute to the inﬂammatory
and demyelinating processes of HAM/TSP or whether the
dominant eﬀect of such cells in vivo is protective against
disease, although these two mechanisms are not mutually
exclusive. Recently, Sabouri et al. reported that a frequency
of CD8+ T cells that were negative for costimulatory
molecules such as CD27, CD28, CD80, CD86, and CD152
was signiﬁcantly higher in patients with HAM/TSP than
in age-matched uninfected controls, but there was no such
diﬀerence between ACs and uninfected controls [67]. They
also found a signiﬁcantly lower frequency of perforin+ cells
and granzyme B+ cells in the CD8+ T cells in HTLV-
1-infected subjects than in uninfected controls, although
there was no signiﬁcant diﬀerence between patients with
HAM/TSP and ACs. Furthermore, the lytic capacity of
HTLV-1-speciﬁcCTLbetweenHAM/TSPandACsestimated
by CD107a mobilization assay showed the signiﬁcantly lower
CD107a staining in HTLV-1-speciﬁc CTL in HAM/TSP than
ACs. These ﬁndings suggest that patients with HAM/TSP
have a high frequency of HTLV-1-speciﬁc CD8+ T cells with
poorlyticcapacity,whereasACshasalowerfrequencyofcells
with high lytic capacity.
4.6. Dendritic Cells (DCs). Dendritic cells are antigen-
presenting cells which play a critical role in the regulation
of the adaptive immune response. In HTLV-1 infection,
it has been shown that the DCs from HAM/TSP patients
were infected with HTLV-1 [68], and the development of
HAM/TSP is associated with rapid maturation of DCs [69].
One of the hallmarks of HTLV-1 infection is the in vitro
proliferation of PBMCs when cultured in the absence of
exogenous antigen or mitogen, referred to as spontaneousInterdisciplinary Perspectives on Infectious Diseases 5
lymphocyte proliferation (SLP), and in HAM/TSP patients,
the levels of SLP reﬂect the severity of the disease [70, 71].
Interestingly, depletion of DCs from the HAM/TSP patient’s
PBMCs abolishes SPL while supplementing DCs, but not
B cells nor macrophages restore proliferation [68]. DC
dependent mechanism of SLP was further supported by data
showing that antibodies to MHC class II, CD86, and CD58
can block SPL [72]. Recently, Jones et al. had demonstrated
that human-derived both myeloid and plasmacytoid DCs are
susceptible to infection with cell-free HTLV-1, and HTLV-
1-infected DCs can rapidly transfer virus to autologous
primary CD4+ T cells [73]. Furthermore, in contrast to the
previous report that CD4+CD25+ T cells are responsible for
the stimulation of Tax-speciﬁc CD8+ T cells [74], it was
recently demonstrated that, compared to the CD4+CD25+
T cells, the DCs are the major cell type responsible for the
generation and maintenance of the Tax-speciﬁc CD8+ Tc e l l s
both in vitro and in vivo [75]. These ﬁndings suggest that
the interaction of DCs with HTLV-1 is also crucial for the
pathogenesis of HAM/TSP.
4.7. The Other Reservoirs of HTLV-1. Previous studies have
indicated that only a small proportion of the monocyte-
macrophagelineagecellsareinfectedwithHTLV-1inperiph-
eral blood [76] and that there has been no direct evidence
indicating that HTLV-1-infected cells of the monocyte-
macrophage lineage cells are present in the CNS [77].
However, monocyte-macrophage lineage cells may also play
important roles in the pathogenesis of HAM/TSP, since it
has been shown that the activation of macrophage and
microglial cells within the CNS closely correlated with the
proviral load within the CNS of HAM/TSP patients [78].
Meanwhile, it was also shown that a vast majority of bone
marrowcellsfromHAM/TSPpatientsarepositiveforHTLV-
1p r o v i r a lD N Ab u tn e g a t i v ef o rv i r a lR N Ae x p r e s s i o n
[79], whereas no HTLV-1 proviral DNA positive CD34+
hematopoietic progenitor cells were detected in ATL patients
[80]. These results suggest that HTLV-1-infected cells within
thebonemarrowmaybeareservoirofHTLV-1inHAM/TSP
patients and play an important role in the etiology of
neuroinﬂammation observed in HAM/TSP [77].
5. Conclusions
As shown in Figure 1, accumulating evidence suggests that
the virus-host immunologic interactions play a pivotal
role in HAM/TSP pathogenesis. Genetically determined less
eﬃcient CTL response against HTLV-1 may cause higher
proviral load and antigen expression in infected individuals,
which lead to activation and expansion of antigen-speciﬁc
T cell responses, subsequent induction of large amounts of
proinﬂammatory cytokines and chemokines, and progres-
sion of HAM/TSP development.
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